Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Pieter Sonneveld, Thierry Façon, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 12, pp. e934-e946
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Noopur Raje, Kenneth C. Anderson, Hermann Einsele, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 73
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
How I treat multiple myeloma in geriatric patients
Thierry Façon, Xavier Leleu, Salomon Manier
Blood (2023) Vol. 143, Iss. 3, pp. 224-232
Open Access | Times Cited: 28
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, et al.
Blood (2022) Vol. 139, Iss. 9, pp. 1409-1412
Open Access | Times Cited: 33
Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy
Brian M. Russell, David Avigan
International Journal of Hematology (2023) Vol. 117, Iss. 5, pp. 652-659
Open Access | Times Cited: 17
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
Ioannis Ntanasis‐Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
HemaSphere (2022) Vol. 6, Iss. 8, pp. e764-e764
Open Access | Times Cited: 25
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
Julius C. Enßle, Julia Campe, Sarah Büchel, et al.
Cancer Cell (2022) Vol. 40, Iss. 6, pp. 587-589
Open Access | Times Cited: 23
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients
Vincenzo Raimondi, Paola Storti, Rosanna Vescovini, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study
Haiqiong Zheng, Han Shi, Yijin Chen, et al.
Bone Marrow Transplantation (2025)
Open Access
The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials
Jennyfa Kadiza Ali, John C. Riches
Cancers (2021) Vol. 13, Iss. 23, pp. 5924-5924
Open Access | Times Cited: 30
Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis
Matthew Ho, Saurabh Zanwar, Francis K. Buadi, et al.
American Journal of Hematology (2022) Vol. 98, Iss. 1, pp. 49-55
Open Access | Times Cited: 20
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
Paola Storti, Valentina Marchica, Rosanna Vescovini, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 17
Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
Margherita Rosati, Evangelos Terpos, Jenifer Bear, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5816-5816
Open Access | Times Cited: 16
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
Harry Alexopoulos, Ioannis P. Trougakos, Meletios Α. Dimopoulos, et al.
European Journal of Internal Medicine (2022) Vol. 107, pp. 7-16
Open Access | Times Cited: 15
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
Andrea Duminuco, Alessandra Romano, Dario Leotta, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
Outcomes of COVID‐19 in multiple myeloma patients treated with daratumumab
Dian Jin, Jingsong He, Wenjun Wu, et al.
Cancer Science (2023) Vol. 115, Iss. 1, pp. 237-246
Open Access | Times Cited: 7
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
Toshiki Terao, Takeshi Yamashita, Ami Fukumoto, et al.
International Journal of Hematology (2022) Vol. 115, Iss. 5, pp. 737-747
Open Access | Times Cited: 11
Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders
Jennifer La, Julie Wu, Westyn Branch‐Elliman, et al.
Blood (2022) Vol. 140, Iss. 7, pp. 782-785
Open Access | Times Cited: 11
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma
Katia Mancuso, Elena Zamagni, Vincenza Solli, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Distal Chronic Inflammatory Demyelinating Polyneuropathy Following COVID-19 Vaccination in a Patient with Solitary Plasmacytoma: A Case Report and Literature Review
Takafumi Kubota, Tomomi Shijo, K Ikeda, et al.
Internal Medicine (2023) Vol. 62, Iss. 16, pp. 2419-2425
Open Access | Times Cited: 5
Immune response and adverse events after vaccination against SARS‐CoV‐2 in adult patients with transfusion‐dependent thalassaemia
Polyxeni Delaporta, Evangelos Terpos, Elena E. Solomou, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 5, pp. 576-579
Open Access | Times Cited: 7
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
Eugenia Abellá, Macedonia Trigueros, Edwards Pradenas, et al.
Life Science Alliance (2022) Vol. 5, Iss. 12, pp. e202201479-e202201479
Open Access | Times Cited: 6
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases
Nicola Sgherza, Paola Curci, Rita Rizzi, et al.
Annals of Hematology (2023) Vol. 103, Iss. 1, pp. 351-355
Closed Access | Times Cited: 3
Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
Damian Mikulski, Paweł Robak, Wiktoria Ryżewska, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 19, pp. 5908-5908
Open Access | Times Cited: 5
Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders
Nathanael R. Fillmore, Jennifer La, Julie Wu, et al.
Blood Advances (2023) Vol. 7, Iss. 21, pp. 6767-6770
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top